Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Biopharmaceutical company retakes control of BPI product from Zephyr Sciences
August 15th, 2005
XOMA Ltd. (XOMA) announced its decision to terminate its exclusive worldwide license agreement with Zephyr Sciences, Inc. (Zephyr) for the research, development and commercialization of products related to bactericidal/permeability increasing protein (BPI), including its NEUPREX product. "BPI's excellent safety profile continues to be an attractive feature in clinical use as evidenced by its ongoing evaluation in both pediatric and adult indications," said John L. Castello, chairman, president and chief executive officer of XOMA. "XOMA remains committed to the future development of BPI and is actively seeking new partnerships with private and public...
Source: Pharma Business Week (2005-08-15)
|
